KRYPTOR-automated angiogenic factor assays and risk of preeclampsia-related adverse outcomes

References

• Sibai B, Dekker G, Kupferminc M. Pre-eclampsia. Lancet. 2005;365(9461):785–799.
   Google Scholar
• Steegers EA, von Dadelszen P, Duvekot JJ, Pijnenborg R. Pre-eclampsia. Lancet. 2010;376(9741):631–644.
   Google Scholar
• Friedman SA, Schiff E, Kao L, Sibai BM. Neonatal outcome after preterm delivery for preeclampsia. Am J Obstetrics Gynecol. 1995;172(6):1785–1788; discussion 8-92.
   Web of Science ®Google Scholar
• Powe CE, Levine RJ, Karumanchi SA. Preeclampsia, a disease of the maternal endothelium: the role of antiangiogenic factors and implications for later cardiovascular disease. Circulation. 2011;123(24):2856–2869.
   PubMed Web of Science ®Google Scholar
• Perni U, Sison C, Sharma V, et al. Angiogenic factors in superimposed preeclampsia: a longitudinal study of women with chronic hypertension during pregnancy. Hypertension. 2012;59(3):740–746.
   PubMed Web of Science ®Google Scholar
• Rolfo A, Attini R, Nuzzo AM, et al. Chronic kidney disease may be differentially diagnosed from preeclampsia by serum biomarkers. Kidney Int. 2013;83(1):177–181.
   PubMed Web of Science ®Google Scholar
• Young B, Levine RJ, Salahuddin S, et al. The use of angiogenic biomarkers to differentiate non-HELLP related thrombocytopenia from HELLP syndrome. J Maternal-fetal Neonatal Med. 2010;23(5):366–370.
   PubMed Web of Science ®Google Scholar
• Verlohren S, Herraiz I, Lapaire O, et al. The sFlt-1/PlGF ratio in different types of hypertensive pregnancy disorders and its prognostic potential in preeclamptic patients. Am J Obstetrics Gynecol. 2012;206( 1):58 e1–e8.
   Google Scholar
• Rana S, Powe CE, Salahuddin S, et al. Angiogenic factors and the risk of adverse outcomes in women with suspected preeclampsia. Circulation. 2012;125(7):911–919.
   PubMed Web of Science ®Google Scholar
• Chaiworapongsa T, Romero R, Korzeniewski SJ, et al. Plasma concentrations of angiogenic/anti-angiogenic factors have prognostic value in women presenting with suspected preeclampsia to the obstetrical triage area: a prospective study. J Maternal-fetal Neonatal Med. 2014;27(2):132–144.
   PubMed Web of Science ®Google Scholar
• Moore AG, Young H, Keller JM, et al. Angiogenic biomarkers for prediction of maternal and neonatal complications in suspected preeclampsia. J Maternal-fetal Neonatal Med. 2012;25(12):2651–2657.
   PubMed Web of Science ®Google Scholar
• Chappell LC, Duckworth S, Seed PT, et al. Diagnostic accuracy of placental growth factor in women with suspected preeclampsia: a prospective multicenter study. Circulation. 2013;128(19):2121–2131.
   PubMed Web of Science ®Google Scholar
• Levine RJ, Maynard SE, Qian C, et al. Circulating angiogenic factors and the risk of preeclampsia. New England J Med. 2004;350(7):672–683.
   PubMed Web of Science ®Google Scholar
• Chaiworapongsa T, Romero R, Espinoza J, et al. Evidence supporting a role for blockade of the vascular endothelial growth factor system in the pathophysiology of preeclampsia. Am J Obstetrics Gynecol. 2004;190(6):1541–1547; discussion 7-50.
   PubMed Web of Science ®Google Scholar
• Chaiworapongsa T, Romero R, Kim YM, et al. Plasma soluble vascular endothelial growth factor receptor-1 concentration is elevated prior to the clinical diagnosis of pre-eclampsia. J Maternal-fetal Neonatal Med. 2005;17(1):3–18.
   PubMed Web of Science ®Google Scholar
• Levine RJ, Lam C, Qian C, et al. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. New England J Med. 2006;355(10):992–1005.
   PubMed Web of Science ®Google Scholar
• Noori M, Donald AE, Angelakopoulou A, Hingorani AD, Williams DJ. Prospective study of placental angiogenic factors and maternal vascular function before and after preeclampsia and gestational hypertension. Circulation. 2010;122(5):478–487.
   PubMed Web of Science ®Google Scholar
• Verlohren S, Galindo A, Schlembach D, et al. An automated method for the determination of the sFlt-1/PIGF ratio in the assessment of preeclampsia. Am J Obstetrics Gynecol. 2010;202(2):161 e1–161 e11.
   PubMed Web of Science ®Google Scholar
• Sunderji S, Gaziano E, Wothe D, et al. Automated assays for sVEGF R1 and PlGF as an aid in the diagnosis of preterm preeclampsia: a prospective clinical study. Am J Obstetrics Gynecol. 2010;202(1):40 e1–40 e7.
   PubMed Web of Science ®Google Scholar
• Benton SJ, Hu Y, Xie F, et al. Angiogenic factors as diagnostic tests for preeclampsia: a performance comparison between two commercial immunoassays. Am J Obstetrics Gynecol. 2011;205(5):469 e1–469 e8.
   PubMed Web of Science ®Google Scholar
• Schiettecatte J, Russcher H, Anckaert E, et al. Multicenter evaluation of the first automated Elecsys sFlt-1 and PlGF assays in normal pregnancies and preeclampsia. Clin Biochem. 2010;43:768–770.
   PubMed Web of Science ®Google Scholar
• van Helden J, Weiskirchen R. Analytical evaluation of the novel soluble fms-like tyrosine kinase 1 and placental growth factor assays for the diagnosis of preeclampsia. Clin Biochem. 2015;48:1113–1119.
   PubMed Web of Science ®Google Scholar
• Andersen LB, Frederiksen-Moller B, Work Havelund K, et al. Diagnosis of preeclampsia with soluble Fms-like tyrosine kinase 1/placental growth factor ratio: an inter-assay comparison. J Am Soc Hypertens. 2015;9(2):86–96.
   PubMed Web of Science ®Google Scholar
• American College of O, Gynecologists, and Task Force on Hypertension in P. Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists’ Task Force on Hypertension in Pregnancy. Obstetrics Gynecol. 2013;122( 5):1122–1131.
   Google Scholar
• Ohkuchi A, Hirashima C, Suzuki H, et al. Evaluation of a new and automated electrochemiluminescence immunoassay for plasma sFlt-1 and PlGF levels in women with preeclampsia. Hypertens Res. 2010;33(5):422–427
   PubMed Web of Science ®Google Scholar